No abstract

Background: Radiosynovectomy is a therapy used to relieve pain and inflammation from rheumatoid arthritis and related diseases. In this study three 188 Re particulate compounds were characterized according to their physico-chemical properties and their biological behavior in rabbits. The results were compared in order to establish which was the radiopharmaceutical that better fits the requirements of this kind of radiotherapy.

Background: Radiosynovectomy is a type of radiotherapy used to relieve pain and inflammation from rheumatoid arthritis. In this study, 188-Rhenium ( 188 Re) colloids were characterized by physical and biological methodologies. This was used to assess which parameters of the kit formulation would be the basis in the development of a more effective radiopharmaceutical for synovectomy. Intraarticular injection in knees of rabbits assessed cavity leakage of activity.

The effectiveness was evaluated for an established wood preservative, zinc borate, prepared in an agitating bead mill to extensively reduce its particle size. The generated micro- or nano-particles of zinc borate were characterized by X-ray powder diffraction, and the particle size distribution was determined to evaluate the effect of milling. Then the fungicidal effectiveness of the zinc borate of both milled and unmilled samples were assayed against brown- and white-rot fungi, on culture medium and on conifer and hardwood as substrates. Treated wood samples were subjected to leaching tests. Scanning electron microscopic images of wood samples were examined to analyze the distribution of zinc borate within the wood. The micronized zinc product kept its crystal structure intact, and it increased the proportion of particles with diameters below 100 nm by 25% when compared to the unmilled product. Malt extract-agar medium supplemented with 2.5% of w/w milled and unmilled zinc borate inhibited fungal growth tested. Both milled and unmilled zinc borate protected the wood when not subjected to leaching. The milled sample of zinc borate improved resistance to leaching, which would allow its application in environments of high moisture content; however, it did not improve the fungicidal action against decay fungi.

Divalproex sodium extended-release dosage form (divalproex-ER) has been promoted as innovative formulation for the treatment of epilepsy and manic disorders, and for migraine headache prevention, with the advantage of being dosing once a day. Due to a significant decreasing in the peak-trough fluctuation of plasma valproic acid levels, in comparison with the twice-daily dosing of conventional delayed-release formulations (divalproex-DR), concentration-dependent side effects would be prevented. However the main constraint for divalproex-ER usage is the need to be administered in a higher daily dose, because of its lower bioavailability, in order to prevent eventual breakthrough seizures when patients are switched from the twice-daily divalproex DR regimen. Taking into account free plasma drug levels, divalproex ER/DR relative bioavailability could be assessed as low as 75% in fasting condition. In order to overcome the need of increase divalproex-ER daily dose, maintenance of the twice-daily regimen is suggested. Divalproex-ER administered every 12 hours not only increases steady state trough concentration to a higher value in comparison with divalproex-DR, avoiding inefficacy of the treatment, but also achieves the safest manner to treat patients with valproic acid because of reaching practically a plateau profile of drug levels.